Therefore, G-6 inhibited the MET/PTEN/TGF-β pathway, mediating these currents contributions to the anti-tumor activity, and showed that G-6 is a promising anti-pancreatic cancer agent candidate potently in vitro. The gene discussed is MET; the disease is familial pancreatic carcinoma.